COMMITMENTS AND CONTINGENCIES (Details) (USD $)	1 Months Ended	12 Months Ended	3 Months Ended			3 Months Ended		1 Months Ended
	Jan. 31, 2013 ANI Pharmaceuticals, Inc	Dec. 31, 2013 ANI Pharmaceuticals, Inc Employee Reduction	Mar. 31, 2013 ANI Pharmaceuticals, Inc Executive Officer Severance Forecast item	Mar. 31, 2013 ANI Pharmaceuticals, Inc Unpaid Annual Bonuses for 2012	Feb. 25, 2013 ANI Pharmaceuticals, Inc Unpaid Annual Bonuses for 2012	Mar. 31, 2013 Antares Pharma, Inc. License	Mar. 31, 2012 Antares Pharma, Inc. License	Dec. 31, 2012 Wake Forest License item
License agreement
Royalties on sales of products						$ 145,040	$ 114,000
Exclusive license received								300,000
Number of patents for which an option for an exclusive license is exercised								3
Accrued bonuses				350,000
Severance costs		1,127,719
Number of executive officers who would be terminated immediately following the completion of the merger			2
Contingent severance payments to executive officers, minimum			770,000		25,000
Contingent severance payments to executive officers, maximum			1,490,100		200,000
Rabbi trust funding	$ 2,300,000
Entitlement period following proposed merger	6 months